AKT1 and cancer: Following T-EV-mediated uptake by recipient cells/tissues, EGFRvIII triggers the mitogen-activated protein kinase (MAPK) and protein kinase B (PKB/Akt) signalling pathways, causing morphological change and boosting malignant tumour development [53].